Workflow
Novo Nordisk Wegovy® users achieved waist and BMI targets linked to improved health and low risk of obesity-related complications

Unlike many other diseases, there are no set guidelines on treatment targets for obesity, and outcomes often rely on percentage weight loss onlyBody mass index (BMI) and waist-to-height ratio (a measurement of unhealthy waist size) represent important obesity treatment targets, associated with a lower risk of obesity-related complicationsA study of people with obesity (STEP UP trial) showed that more people taking Wegovy® achieved a BMI under 27 and a waist-to-height ratio of less than 0.53, compared to non ...